SVB Leerink Maintains Outperform Rating for Deciphera Pharmaceuticals: Here's What You Need To Know

SVB Leerink has decided to maintain its Outperform rating of Deciphera Pharmaceuticals DCPH and raise its price target from $21.00 to $25.00.

Shares of Deciphera Pharmaceuticals are trading up 10.06% over the last 24 hours, at $19.90 per share.

A move to $25.00 would account for a 25.63% increase from the current share price.

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals Inc is a biotechnology company, which develops and manufactures kinase-inhibiting drugs for the treatment of cancers and immunological diseases. It holds a diverse pipeline of drug candidates that includes three clinical-stage and two research-stage programs. Its lead drug candidate DCC-2618 is designed to inhibit the full spectrum of mutant or amplified KIT and Pdgfra kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. In addition, it is also developing two other clinical-stage drug candidates, DCC-3014 and Rebastinib. Geographically all the operations function through the region of the United States.

About Analyst Ratings

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along with analyst success scores in Benzinga Pro.

This article was generated by Benzinga's automated content engine and reviewed by an editor.